Anacetrapib is a CETP inhibitor being developed by Merck to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Anacetrapib is a cholesterol ester transfer protein (CETP) inhibitor that blocks the transfer of cholesterol from highdensity lipoprotein to other lipoproteins. This results in an increase in high-density lipoprotein cholesterol (HDL-C) and a decrease in lowdensity lipoprotein cholesterol (LDL-C), which may reduce the development of atherosclerosis. Anacetrapib has not been approved for sale in Canada or the United States. Clinical evidence to support the use of anacetrapib for dyslipidemia has been reported in two clinical trials. REVEAL is an ongoing, large-scale phase 3 trial evaluating the effectiveness of anacetrapib with a statin for the secondary prevention of major coronary events in patients who have a history of cardiovascular disease. Results are anticipated in January 2017.

Elgodipine (IQB-875, CAS 119413-55-7) is a phenyldihydropyridine derivative acting as a calcium channel antagonist. Elgodipine inhibited both T- and L-type calcium channels in a concentration-dependent manner. Elgodipine was in clinical trials for the treatment of cardiovascular diseases however its development has been discontinued.

Dipiproverine is the spasmolytic agent. It was used as anticholinergic drug.

Acolbifene, the active metabolite of EM-800, was identified as a pure antagonist that acts on both activation domains of the ERs. It is in Phase III clinical trials for the prevention of breast cancer and vasomotor symptoms (Hot flush) in postmenopausal women. Most commonly reported adverse events included irregular menses, leg/muscle cramps, diarrhea, and hot flashes. No serious adverse events were reported.

An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma, glioma and liver cancer. The most common adverse events are nausea and asthenia, vomiting, myasthenic syndrome, dehydration, hypophosphatemia, cytolytic hepatitis and plantar fasciitis.

Diphenan is p-benzyl-phenyl-carbamate. Various workers have reported that diphenan will rid children of oxyurids and it has been claimed to be nontoxic and tasteless and to have the advantage of being a vermicide as opposed to a vermifuge. An attempt has been made to assess the efficacy of diphenan as a vermicide. Diphenan was given far in excess of the normal dosage. Subsequent examnation showed few cures and these mostly in lightly infested children. The condition of many was unchanged and that of some worse after treatment. No toxic reactions were encountered. Moreover, diphenan was found to have no detectable anthelmintic effect when given in high dosage in the treatment of enterobiasis.

XL418 is a dual protein kinase B (Akt) and ribosomal protein S6 Kinase (p70 S6K) inhibitor that also acts as an ATP-pocket binder with potential antineoplastic activity. XL418 was involved in phase I clinical trial in patients with solid tumors, however, in Dec 2007, this study was discontinued, due to low drug exposure.

Crufomate is an insecticide and antihelmintic drug which acts by inhibition of acetylcholinesterase. Crufomate was used on or in cattle, sheep, and goats to control internal cattle grubs and external horn flies and cattle lice. Crufomate is administered by injection, oral administration, and spraying. For the treatment of internal helminth parasites, crufomate is administered by the oral drench directly into the rumen.